Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome

Journal of Allergy and Clinical Immunology

Volumn 97, Issue 1 I, 1996, Pages 119-126

  Steinberg, Paul ^a   McNutt, Bruce E ^b   Marshall, Paul ^a   Schenck, Carlos ^a   Lurie, Nicole ^a   Pheley, Alfred ^a   Peterson, Phillip K ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b Marion Merrell Dow Inc   (United States)

Author keywords

antihistamines; atopy; Chronic fatigue syndrome; delayed skin tests; immediate skin tests; terfenadine

Indexed keywords

DOXEPIN; HISTAMINE H2 RECEPTOR; PLACEBO; TERFENADINE;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HISTAMINE RELEASE; HUMAN; HYPERSENSITIVITY; INCIDENCE; MENTAL FUNCTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOMETRY; QUESTIONNAIRE; SELF CONCEPT;

EID: 0030026392     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70290-7     Document Type: Article

References (38)

1. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT, Brus I. Chronic fatigue syndrome: a working case definìtion. Ann Intern Med 1988; 108:387-9.
2. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Inf Dis 1991;13(suppl 1)8-11.
3. Peterson PK, Schenck CH, Sherman R. Chronic fatigue syndrome in Minnesota. Minnesota Med 1991;74:21-6.
4. Straus SE, Dale JK, Wright R, Metcalfe DD. Allergy and the chronic fatigue syndrome. J ALLERGY CLIN IMMUNOL 1988;81:791-5.
5. Lloyd AR, Wakefield D, Boughton CR, Dwyer JM. Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 1989;151:122-4.
6. Tobi M, Morag A, Ravid Z, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1982;1:61-4.
7. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1984;102:7-16.
8. Gupta S, Vayuvegula B. A comprehensive immunological analysis in chronic fatigue syndrome. Scand J Immunol 1991;33(3):319-27.
9. Landay AL, Jessop C, Lennette ET, et al. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991;338(8769):707-12.
10. Meni I, Villaneuva-Meyer J. Study of cerebral perfusion by neuroSPECT in patients with chronic fatigue syndrome. In: Hyde BM, ed. The clinical and scientific basis of myalgic encephalomyelitis/chronic fatigue syndrome. Ottawa, Canada: Nightingale Research Foundation, 1992;432-8.
11. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73(6):1224-34.
12. Lloyd A, Hickie I, Brockman A, et al. Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects. [Letter] J Infect Dis 1991;164(5):1023-4.
13. Bakheit AM, Behan PO, Watson WS, et al. Abnormal arginine-vasopressin secretion and water metabolism in patients with post-viral fatigue syndrome. Acta Neurol Scand 1993;87(3):234-8.
14. Demitrack M, Gold PW, Dale JK, et al. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry 1992;32:1067-77.
15. Hirata-Dulas CAI, Halstenson CE, Peterson PK. Medical therapy of chronic fatigue syndrome. In: S Straus, ed. Chronic fatigue syndrome. New York: Marcel Dekker, Inc., 1994;387-404.
16. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-8.
17. Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990;89:554-60.
18. Clark S, Tindall E, Bennett R. A double blind crossover study of prednisone in the treatment of fibrositis. Arthritis Rheum 1984;27:S76.
19. Suhadolnik RJ, Sobol RW, Reichenbach NL, Strayer DR, Gillespie D, Carter WA. Mismatched dsRNA: clinical applications in HIV disease and chronic fatigue syndrome (CFIDS). Program supplement to the 31st International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology 1991:S74.
20. Jones JF. Chronic Epstein-Barr virus infection. Ann Rev Med 1987;38:195-209.
21. Richelson E. Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc 1983;58:40-6.
22. 1 receptor antagonist treatment of chronic rhinitis. J ALLERGY CLIN IMMUNOL 1988;81:975-80.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch of General Psychiatry 1961;4:561-71.
24. Zung WWK. A self-rating depression scale. Arch of General Psychiatry 1965;12:63-70.
25. Derogatis LR, SCL-90 administration, scoring and procedures manual I. Baltimore: Johns Hopkins University Press, 1977.
26. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-31.
27. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989;262:907-13.
28. Norman PS. Skin testing. In: Rose NR, DeMacario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology, 4th ed. Washington, DC: American Society for Microbiology, 1992;685-8.
29. Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergy dose-response curve and effect of wheal, erythema, and patient selection on assay results. J ALLERGY CLIN IMMUNOL 1982;70:343-52.
30. Smith DL, DeShazo RD. Delayed hypersensitivity skin testing. In: Rose NR, DeMacario EC, Fahey JL, Firedman H, Penn GM, eds. Manual of clinical laboratory immunology, 4th ed. Washington, DC: American Society for Microbiology 1992;202-6.
31. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988;157:405-12.
32. Chan-Yeung M, Vedal S, Lam S, Enarson D. Immediate skin reactivity and its relationship to age, sex, smoking, and occupational exposure. Arch Environ Health 1985;40:53-7.
33. Gergen PJ, Turkeltaub PC, Kovar MG. The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population: results from the second national health and nutrition examination survey. J ALLERGY CLIN IMMUNOL 1987;80:669-79.
34. Strannegard I-L, Strannegard O. Epstein-Barr virus antibodies in children with atopic disease. Int Arch Allergy Appl Immunol 1981;64:314-9.
35. Rystedt I, Strannegard I-L, Strannegard O. Increased seram levels of antibodies to Epstein-Barr virus in adults with history of atopic dermatitis. Int Arch Allergy Appl Immunol 1984;75:179-83.
36. Kniker WT, et al. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell mediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A. Ann Allergy 1984;52:75-82.
37. Davis W, Engler RJM, Moyer D, Smith L, Wierzba T, Birx D. Comparison between multitest Merieux Inst. and intradermal delayed type hypersensitivity skin tests in HIV seropositive patients. J ALLERGY CLIN IMMUNOL 1991;87:266.
38. Kemp JP, Buckley CD, Gershwin ME. Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985;54:502-9.